CD44 and cancer: Therefore, the wide expression of CD44 in normal tissues is a complicating factor in CD44 antibody-conjugated drug-induced toxic epidermal necrolysis and hematologic toxicity, thus making selective and safe antibody-based cancer therapy impossible.